UCTV Seminars

description:

There are too few donated livers for all the people who need them, and organ transplants come at significant risk of rejection. With those limitations in mind, UCSF researcher Holger Willenbring has been trying to use stem cell-derived liver cells, or hepatocytes, as the tissue source for treating liver disease. UCSF clinical fellow Andrew Grimm speaks about the standard of care for liver disease and a young woman who has battled liver disease shares her insights.

more on this subject:

Entering the RNA World with Sidney Altman

Cancer Nanotechnology - Opportunities and Challenges - View from the NCI Alliance for Nanotechnology in Cancer

Encoding Contingency

see all from Cell and Developmental Biology >

host links:

California Institute for Regenerative Medicine (CIRM)